Portal de Periódicos da CAPES

First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans

2022; BioMed Central; Volume: 20; Issue: 1 Linguagem: Inglês

10.1186/s12969-022-00768-6

1546-0096

Timothy Beukelman, George Tomlinson, Peter A. Nigrović, Anne Dennos, Vincent Del Gaizo, Marian Jelinek, Mary Ellen Riordan, Laura E. Schanberg, S. Mohan, Erin Pfeifer, Yukiko Kimura, R. Agbayani, S. Akoghlanian, E. Allenspach, E. L. Anderson, Stacy P. Ardoin, S. Armendariz, Imelda Balboni, L. Ballenger, Susan H. Ballinger, Fatima Barbar‐Smiley, K. Baszis, H. Bell-Brunson, Heather Benham, W. Bernal, T. Bigley, Bryce A. Binstadt, M. Blakley, John F. Bohnsack, Austin L. Brown, Michael Buckley, Danielle R. Bullock, Bonnie Cameron, Scott Canna, Elaine Cassidy, Joyce C. Chang, Vishal Chauhan, T. Chinn, Peter Chira, Annie Cooper, Jennifer C. Cooper, C. Correll, L. Curiel-Duran, M. Curry, Annette Dalrymple, Deirdre De Ranieri, F. Dedeoglu, Marietta DeGuzman, N. Delnay, V. Dempsey, James J. Dowling, J. Drew, K. Driest, Qing Du, D. Durkee, M. Eckert, Cuoghi Edens, M. Elder, S. Fadrhonc, Leslie Favier, Brian M. Feldman, I. Ferguson, Bruno Ferreira, L. Fogel, Emily Fox, Robert C. Fuhlbrigge, J. Fuller, Nancy George, Dana Gerstbacher, M. Gillispie-Taylor, Y. Ingrid Goh, Donald P. Goldsmith, Sriharsha Grevich, T A Griffin, Myriam Guevara, P. Guittar, Marlene Hager, Taeho Hahn, O. Halyabar, M. Hance, S. Haro, Julia G. Harris, Jonathan S. Hausmann, Kristen Hayward, Lauren A. Henderson, Aimee O. Hersh, S. Hillyer, L. Hiraki, M. Hiskey, Patricia M. Hobday, C. Hoffart, Michael J. Holland, M. Hollander, M. J. Horwitz, Joyce Hsu, Adam M. Huber, M. Ibarra, C. Inman, Sharon Jackson, Kenneth James, Ginger Janow, Susan Jones, Kenneth T. Jones, Jordan T. Jones, C. Justice, U. Khalsa, Bernadette Kienzle, S. Kim, Y. Kimura, Maleewan Kitcharoensakkul, T. Klausmeier, K. E. Klein, Marisa S. Klein‐Gitelman, S. Kramer, Jennifer C. Lai, Bianca Lang, Sivia Lapidus, Erica Lawson, Ronald M. Laxer, P. Lee, T. Lee, Melissa A. Lerman, Deborah M. Levy, S. Li, Chun‐Ying Lin, Nicholas Ling, Mei‐Chen Lo, S. Lvovich, J. Maller, A. Martyniuk, K. John McConnell, I. McHale, Esra Meidan, Elizabeth Mellins, Marlene R. Miller, R. Modica, Karen D. Moore, T. Moussa, V. Mruk, Eyal Muscal, Kavita Nanda, Lorien Nassi, Jessica Neely, L. Newhall, Peter A. Nigrović, B. Nolan, Edward J. Oberle, O. Okeke, Melissa Oliver, Kathleen M. O’Neil, R. Oz, Amy S. Paller, Jayesh Patel, Peri H. Pepmueller, K. Phillippi, Rajdeep Pooni, S. Protopapas, B. Puplava, S. Radhakrishna, Suzanne Ramsey, H. Reid, Sarah Ringold, M. Riordan, Mona Riskalla, M. Ritter, Manuela Rodriquez, K. Rojas, Margalit Rosenkranz, Tamar B. Rubinstein, C. Sandborg, Lisabeth V. Scalzi, K. Schikler, Kara Schmidt, E. Schmitt, Rayfel Schneider, C. Seper, J. Shalen, R. Sheets, S. Shenoi, J. Shirley, Earl D. Silverman, Vidya Sivaraman, Chelsey Smith, Jennifer B. Soep, Min‐Jeong Son, Lynn Spiegel, H. Stapp, Sara Stern, A. Stevens, Bruce R. Stevens, K. Stewart, Elizabeth Stringer, R. Sundel, M. Sutter, Saad Syed, Saad Syed, T. Tanner, G. Tarshish, S. Tarvin, Melissa Tesher, Akaluck Thatayatikom, B. Thomas, Dana Toib, Kathryn S. Torok, C. Toruner, Shirley M. L. Tse, T. Valcarcel, N. Vasquez, Richard K. Vehe, J. Velez, Emily von Scheven, Sheetal S. Vora, Linda Wagner‐Weiner, D. Wahezi, Michael Waterfield, P. Weiss, J. Weiss, Andrew J. White, Leandra Woolnough, Tracey Wright, M. Yee, Rae S. M. Yeung, K. Yomogida, Yongdong Zhao, Austin Zhu,

Acute Lymphoblastic Leukemia research

Abstract Background The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed consensus treatment plans (CTPs) to compare treatment initiation strategies for systemic juvenile idiopathic arthritis (sJIA). First-line options for sJIA treatment (FROST) was a prospective observational study to assess CTP outcomes using the CARRA Registry. Methods Patients with new-onset sJIA were enrolled if they received initial treatment according to the biologic CTPs (IL-1 or IL-6 inhibitor) or non-biologic CTPs (glucocorticoid (GC) monotherapy or methotrexate). CTPs could be used with or without systemic GC. Primary outcome was achievement of clinical inactive disease (CID) at 9 months without current use of GC. Due to the small numbers of patients in the non-biologic CTPs, no statistical comparisons were made between the CTPs. Results Seventy-three patients were enrolled: 63 (86%) in the biologic CTPs and 10 (14%) in the non-biologic CTPs. CTP choice appeared to be strongly influenced by physician preference. During the first month of follow-up, oral GC use was observed in 54% of biologic CTP patients and 90% of non-biologic CTPs patients. Five (50%) non-biologic CTP patients subsequently received biologics within 4 months of follow-up. Overall, 30/53 (57%) of patients achieved CID at 9 months without current GC use. Conclusion Nearly all patients received treatment with biologics during the study period, and 46% of biologic CTP patients did not receive oral GC within the first month of treatment. The majority of patients had favorable short-term clinical outcomes. Increased use of biologics and decreased use of GC may lead to improved outcomes in sJIA.